Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
All content for Lean By Design is the property of Oscar Gonzalez & Lawrence Wong and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
0118. Transformative Strategies for Scaling Operations in Biopharma Part 2
Lean By Design
13 minutes
1 year ago
0118. Transformative Strategies for Scaling Operations in Biopharma Part 2
Send us a text Ever wondered how continuous improvement can propel your organization's growth to new heights? In this episode of Lean by Design, host Oscar Gonzalez delves into innovative strategies drawn from recent projects. Discover how you can transform data into meaningful metrics that drive success and ensure everyone is aligned with clear, visible guidelines. Explore actionable tips for leveraging comprehensive checklists and team guidance to enhance workflow efficiency. Learn how maki...
Lean By Design
Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
